Researchers identify strategy for overcoming resistance to RAS-targeted cancer drugs

by Roswell Park Comprehensive Cancer Center

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

Researchers at Roswell Park Comprehensive Cancer Center have identified a promising strategy for overcoming one of the biggest challenges facing KRAS-targeted cancer therapies: treatment resistance. Results of the preclinical study, led by Roswell Park faculty members Vishnu Kumarasamy, Ph.D., Agnieszka Witkiewicz, M.D., and Erik Knudsen, Ph.D., were published in Cancer Research.

Targeted therapies against KRAS and RAS have transformed the treatment landscape for patients with pancreatic, lung and other cancers. However, their benefits can be limited when cancer cells develop resistance and tumors begin to grow again.

To better understand how that resistance develops, the Roswell Park team used transcriptomic, proteomic and functional analyses in multiple cancer models. The researchers found that even when RAS signaling was successfully blocked, cancer cells could maintain cell proliferation by activating alternative pathways. Persistent cell-cycle activity emerged as a common feature of resistant tumors.

The team then demonstrated that blocking the key cell-cycle regulators CDK4/6 or CDK2 kinases restored sensitivity to KRAS- and RAS-targeted therapies. Combination approaches produced more durable tumor control in laboratory and animal models than KRAS inhibition alone.

"The FDA approval of the RAS inhibitor daraxonrasib marks an important advance in cancer treatment, but acquired resistance remains a major challenge," says first author Kumarasamy, research assistant professor of oncology in the Department of Molecular & Cellular Biology.

"Our findings show that sustained cell cycle represents a common vulnerability that can be therapeutically exploited to overcome resistance and improve treatment durability."

The findings may help guide future clinical strategies aimed at extending the effectiveness of KRAS-targeted medicines and delaying disease progression.

"By co-targeting critical cell-cycle regulators, we may be able to create more durable responses and overcome an important mechanism of drug resistance," adds co-senior author Witkiewicz, professor of oncology and personalized medicine in the Department of Molecular and Cellular Biology.

Publication details

Vishnu Kumarasamy et al., Targeting Distinct Cell-Cycle Nodes Overcomes RAS Inhibitor Resistance, Cancer Research (2026). DOI: 10.1158/0008-5472.can-26-1315

Journal information: Cancer Research

Clinical categories

OncologyClinical pharmacology Provided by Roswell Park Comprehensive Cancer Center Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Researchers identify strategy for overcoming resistance to RAS-targeted cancer drugs (2026, November 2) retrieved 2 November 2026 from https://medicalxpress.com/news/2026-11-strategy-resistance-ras-cancer-drugs.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.